[HTML][HTML] Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese …
Y Deng, P Chi, P Lan, L Wang, W Chen… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE In the multicenter, open-label, phase III FOWARC trial, modified infusional
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher …
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher …
Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: A randomized clinical trial
…, V Hallett, JA Mulick, B Green, B Handen, Y Deng… - Jama, 2015 - jamanetwork.com
Importance Disruptive behavior is common in children with autism spectrum disorder. Behavioral
interventions are used to treat disruptive behavior but have not been evaluated in large-…
interventions are used to treat disruptive behavior but have not been evaluated in large-…
BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing
The tumour suppressor complex BRCA1–BARD1 functions in the repair of DNA double-stranded
breaks by homologous recombination. During this process, BRCA1–BARD1 facilitates …
breaks by homologous recombination. During this process, BRCA1–BARD1 facilitates …
[PDF][PDF] Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial …
Y Deng, P Chi, P Lan, L Wang, W Chen… - Journal of clinical …, 2016 - researchgate.net
Purpose Total mesorectal excision with fluorouracil-based preoperative chemoradiotherapy
and postoperative chemotherapy is a standard treatment of locally advanced rectal cancer. …
and postoperative chemotherapy is a standard treatment of locally advanced rectal cancer. …
Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial
J Li, S Qin, RH Xu, L Shen, J Xu, Y Bai, L Yang, Y Deng… - Jama, 2018 - jamanetwork.com
Importance Patients with metastatic colorectal cancer (CRC) have limited effective and
tolerable treatment options. Objective To evaluate the efficacy and safety of oral fruquintinib, a …
tolerable treatment options. Objective To evaluate the efficacy and safety of oral fruquintinib, a …
Abnormal liver tests in COVID‐19: a retrospective observational cohort study of 1,827 patients in a major US hospital network
MA Hundt, Y Deng, MM Ciarleglio, MH Nathanson… - …, 2020 - Wiley Online Library
Background and Aims The coronavirus‐19 disease (COVID‐19) pandemic, caused by the
severe acute respiratory syndrome coronavirus 2 virus, is associated with significant morbidity …
severe acute respiratory syndrome coronavirus 2 virus, is associated with significant morbidity …
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal …
…, S Luo, W Deng, L Ling, H Liu, Y Deng - The lancet …, 2022 - thelancet.com
Background PD-1 blockade is highly effective in patients with mismatch repair-deficient or
microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 …
microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 …
Early assessment of lung cancer immunotherapy response via circulating tumor DNA
Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer
Immune checkpoint inhibitor (ICI) therapy can induce complete responses in mismatch
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs). …
repair-deficient and microsatellite instability-high (d-MMR/MSI-H) colorectal cancers (CRCs). …
[HTML][HTML] Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial
…, H Yan, Q Liu, F Yang, W Wei, Y Deng… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Camrelizumab is an antibody against programmed death protein 1. We assessed
the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular …
the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular …
